NO20034007D0 - N-fenylarylsulfonamidforbindelse, legemiddel inneholdende forbindelsen somaktiv bestanddel, mellomprodukt for forbindelsen, ogfremgangsmåter for fremstilling av samme - Google Patents

N-fenylarylsulfonamidforbindelse, legemiddel inneholdende forbindelsen somaktiv bestanddel, mellomprodukt for forbindelsen, ogfremgangsmåter for fremstilling av samme

Info

Publication number
NO20034007D0
NO20034007D0 NO20034007A NO20034007A NO20034007D0 NO 20034007 D0 NO20034007 D0 NO 20034007D0 NO 20034007 A NO20034007 A NO 20034007A NO 20034007 A NO20034007 A NO 20034007A NO 20034007 D0 NO20034007 D0 NO 20034007D0
Authority
NO
Norway
Prior art keywords
compound
methyl
preparing
processes
active ingredient
Prior art date
Application number
NO20034007A
Other languages
English (en)
Other versions
NO329682B1 (no
NO20034007L (no
Inventor
Atsushi Naganawa
Tetsuji Saitoh
Kaoru Kobayashi
Takayuki Maruyama
Yoshihiko Nakai
Yoshihiko Hashimoto
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of NO20034007D0 publication Critical patent/NO20034007D0/no
Publication of NO20034007L publication Critical patent/NO20034007L/no
Publication of NO329682B1 publication Critical patent/NO329682B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/70Sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/04Drugs for disorders of the urinary system for urolithiasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Furan Compounds (AREA)
NO20034007A 2001-03-12 2003-09-10 N-fenylarylsulfonamidforbindelse, og antagonist av EP1 reseptor og farmasoytisk preparat omfattende forbindelsen som aktiv bestanddel NO329682B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001068498 2001-03-12
JP2001281569 2001-09-17
JP2002007760 2002-01-16
PCT/JP2002/002245 WO2002072564A1 (fr) 2001-03-12 2002-03-11 Compose de n-phenylarylsulfonamide, medicament contenant le compose en tant que principe actif, intermediaire pour le compose et ses procedes de production

Publications (3)

Publication Number Publication Date
NO20034007D0 true NO20034007D0 (no) 2003-09-10
NO20034007L NO20034007L (no) 2003-11-12
NO329682B1 NO329682B1 (no) 2010-11-29

Family

ID=27346214

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034007A NO329682B1 (no) 2001-03-12 2003-09-10 N-fenylarylsulfonamidforbindelse, og antagonist av EP1 reseptor og farmasoytisk preparat omfattende forbindelsen som aktiv bestanddel

Country Status (24)

Country Link
US (3) US7235667B2 (no)
EP (2) EP1612208B1 (no)
JP (3) JP3555620B2 (no)
KR (1) KR100886854B1 (no)
CN (1) CN1294126C (no)
AT (2) ATE522513T1 (no)
AU (1) AU2002238855B2 (no)
BR (1) BR0208027A (no)
CA (1) CA2439604C (no)
CZ (1) CZ304035B6 (no)
DE (1) DE60220255T2 (no)
DK (2) DK1612208T3 (no)
ES (1) ES2286230T3 (no)
HU (1) HU230056B1 (no)
IL (2) IL157701A0 (no)
MX (1) MXPA03008134A (no)
NO (1) NO329682B1 (no)
NZ (1) NZ528120A (no)
PL (1) PL218750B1 (no)
PT (2) PT1612208E (no)
RU (1) RU2299202C2 (no)
TW (1) TWI317359B (no)
WO (1) WO2002072564A1 (no)
ZA (1) ZA200306884B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022549A1 (ja) * 2002-09-09 2004-03-18 Ono Pharmaceutical Co., Ltd. 4−メチル−1,3−チアゾール−2−イルスルホニルハライドの製造方法
CA2514220C (en) * 2003-01-29 2012-02-28 Pharmagene Laboratories Limited Ep4 receptor antagonists
GB0317500D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Treatment of bph
JPWO2005000356A1 (ja) * 2003-06-27 2006-08-03 小野薬品工業株式会社 尿路疾患治療剤
GB0401334D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
WO2006004115A1 (ja) * 2004-07-05 2006-01-12 Chugai Seiyaku Kabushiki Kaisha 過活動膀胱治療剤
JP2008189549A (ja) * 2005-05-12 2008-08-21 Astellas Pharma Inc カルボン酸誘導体またはその塩
JP2009057282A (ja) * 2005-12-19 2009-03-19 Astellas Pharma Inc カルボン酸誘導体又はその塩
TW200817319A (en) * 2006-08-10 2008-04-16 Astellas Pharma Inc Sulfonamide compound or salt thereof
NZ578988A (en) * 2007-02-16 2012-03-30 Ono Pharmaceutical Co Therapeutic agent for urinary excretion disorder
PT2177512E (pt) * 2007-08-01 2012-05-07 Taisho Pharmaceutical Co Ltd Inibidor da ligação de s1p1
JP2010043063A (ja) * 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
US8314240B2 (en) * 2008-06-23 2012-11-20 Astellas Pharma Inc. Sulfonamide compounds or salts thereof
TW201107309A (en) * 2009-07-27 2011-03-01 Kissei Pharmaceutical Indole derivatives, or the pharmaceutically acceptable salts
EP2598481B1 (en) * 2010-07-26 2016-08-31 Bristol-Myers Squibb Company Sulfonamide compounds useful as cyp17 inhibitors
JP5363636B2 (ja) * 2011-10-21 2013-12-11 ファイザー・リミテッド 新規な塩および医学的使用
US20140039004A1 (en) * 2012-07-31 2014-02-06 Ono Pharmaceutical Co., Ltd. Method of treating of gastroesophageal reflux disease
JP6103893B2 (ja) * 2012-11-15 2017-03-29 サントリー食品インターナショナル株式会社 コーヒーオイルの製造方法
CN106660063B (zh) * 2014-04-30 2019-06-18 佩纳尔维工业有限公司 用于将液体应用于不同形状的盖子上的可编程同心头
KR102245930B1 (ko) * 2015-11-13 2021-04-29 주식회사 대웅제약 소디움 채널 차단제
RU2659955C1 (ru) * 2017-10-26 2018-07-04 Галина Ильхамовна Лукина Способ диагностики высоких гастроэзофагеальных рефлюксов

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2419923A1 (de) * 1973-04-28 1974-11-28 Fujisawa Pharmaceutical Co Sulfonsaeureester, verfahren zu deren herstellung und verwendung derselben als kondensationsmittel
JPS5748534B2 (no) 1974-03-04 1982-10-16
DE2555048A1 (de) * 1975-12-06 1977-06-30 Pfersee Chem Fab Verfahren und vorrichtung zur herstellung bestaendiger, waessriger emulsionen wasserunloeslicher substanzen
JPS5293469A (en) 1976-02-02 1977-08-05 Fuji Photo Film Co Ltd Method of curing gelatin
JPH05293469A (ja) 1992-04-17 1993-11-09 Toda Constr Co Ltd 滅菌精製水の製造方法およびその装置
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
AU4431400A (en) * 1999-05-12 2000-12-05 Japan As Represented By President Of National Cancer Center Anticancer agents containing ep1 antagonists as the active ingredient
KR20020012639A (ko) 1999-07-29 2002-02-19 우에노 도시오 술폰아미드 유도체 및 알로디니아 치료제
EP1369129A4 (en) 2001-03-14 2005-08-03 Ono Pharmaceutical Co ANTIDEPRESSOR REMEDIES CONTAINING AN EP1 ANTAGONIST AS ACTIVE INGREDIENT

Also Published As

Publication number Publication date
JP2004149545A (ja) 2004-05-27
WO2002072564A1 (fr) 2002-09-19
DK1369419T3 (da) 2007-09-24
IL157701A (en) 2010-06-30
MXPA03008134A (es) 2004-03-10
RU2299202C2 (ru) 2007-05-20
TWI317359B (en) 2009-11-21
NZ528120A (en) 2006-05-26
US7629369B2 (en) 2009-12-08
PT1612208E (pt) 2011-10-12
DE60220255D1 (de) 2007-07-05
US8088802B2 (en) 2012-01-03
CA2439604A1 (en) 2002-09-19
CZ304035B6 (cs) 2013-08-28
CN1509278A (zh) 2004-06-30
HU230056B1 (hu) 2015-06-29
RU2003127677A (ru) 2005-03-27
EP1612208B1 (en) 2011-08-31
HUP0400155A2 (hu) 2004-08-30
HUP0400155A3 (en) 2007-05-02
US7235667B2 (en) 2007-06-26
DK1612208T3 (da) 2011-12-12
JP3741120B2 (ja) 2006-02-01
US20060030713A1 (en) 2006-02-09
US20100041708A1 (en) 2010-02-18
PL218750B1 (pl) 2015-01-30
ATE362924T1 (de) 2007-06-15
EP1369419A1 (en) 2003-12-10
AU2002238855B2 (en) 2007-12-06
PL365100A1 (en) 2004-12-27
NO329682B1 (no) 2010-11-29
ES2286230T3 (es) 2007-12-01
CZ20032452A3 (cs) 2003-11-12
NO20034007L (no) 2003-11-12
EP1612208A3 (en) 2006-12-06
EP1369419B1 (en) 2007-05-23
CN1294126C (zh) 2007-01-10
ZA200306884B (en) 2005-03-30
CA2439604C (en) 2012-05-01
JP2006028193A (ja) 2006-02-02
BR0208027A (pt) 2004-12-28
US20050124672A1 (en) 2005-06-09
JPWO2002072564A1 (ja) 2004-07-02
KR20030082978A (ko) 2003-10-23
JP4432051B2 (ja) 2010-03-17
JP3555620B2 (ja) 2004-08-18
KR100886854B1 (ko) 2009-03-05
EP1369419A4 (en) 2005-03-16
DE60220255T2 (de) 2008-01-17
EP1612208A2 (en) 2006-01-04
PT1369419E (pt) 2007-08-16
IL157701A0 (en) 2004-03-28
ATE522513T1 (de) 2011-09-15

Similar Documents

Publication Publication Date Title
NO20034007D0 (no) N-fenylarylsulfonamidforbindelse, legemiddel inneholdende forbindelsen somaktiv bestanddel, mellomprodukt for forbindelsen, ogfremgangsmåter for fremstilling av samme
DE60018064D1 (de) Substituierte phenylpropionsäurederivate als agonisten des menschlichen peroxisom-proliferator-aktiverten rezeptors alpha(ppar)
JP2010530431A5 (no)
GEP20094723B (en) Tetraazabenzo [e] azulene derivatives and analogs thereof
NO20032510D0 (no) Organiske forbindelser
NZ514661A (en) alpha-substituted carboxylic acid derivatives and their use as therapeutic agents in pharmaceutical compositions
DK1326613T4 (da) Anvendelse af substituerede imidazo[1,2-a] pyridin-, -pyrimidin- og -pyrazin-3-yl-amin-derivater til fremstilling af lægemidler til NOS-inhibering
ATE264337T1 (de) Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung
NO20050667L (no) N-substituerte-1H-indol-5-propionsyreforbindelser som PPAR agonister nyttige for behandling av diabetes
SE0102036D0 (sv) Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
WO2003063791A3 (en) Non-steroidal analogs of 2-methoxyestradiol
DE60039878D1 (de) XENON ALS NMDA-ANTOGONIST zur Neuroprotektion
DE60022895D1 (de) Pdgf-rezeptor-kinase hemmende verbindungen, deren herstellung, reinigung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
WO2002060423A3 (en) Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists
EP1348698A4 (en) SUBSTITUTED CARBOXYLENE DERIVATIVES
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
Yu et al. Uptake and release effects of diethylpropion and its metabolites with biogenic amine transporters
WO2003018010A1 (fr) Agent prophylactique et/ou curatif pour les maladies induites par l'activite de l'arteriosclerose
WO1999004770A3 (en) A pharmaceutical composition active in reducing production of mcp-1 protein
EP1149832A4 (en) BENZAMIDE DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING THEM
AR016070A1 (es) Forma polimorfica cristalina 1 del compuesto sal acetato de metil-n3-[2-{3-4-(formamidinofenil)-isoxazolin-5(r)-il}-acetil]-n2-(n-butiloxicarbonil)-2,3-(s)-diaminopropionato (roxifiban), composicion farmaceutica que lo contiene y su uso para preparar un medicamento que inhibe la union de una protein
ATE247963T1 (de) Medikament zur behandlung von glaukoma und ischämischer retinopathie
EP1172106A3 (en) Use of fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles as substance P receptor antagonists
JP2003012516A5 (no)
JP2006503049A5 (no)

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees